Novartis.jpg” />

Novartis has acquired US-based hematologic and inflammatory disorder theraputics developer Selexys Pharmaceuticals in a deal valued at approximately $665m.

The company exercised its acquisition right after receiving results of the Sustain study, a Phase II trial evaluating the use of an anti-P-selectin antibody called SelG1, in the reduction of vaso-occlusive pain crises in patients with sickle-cell disease (SCD).

Novartis oncology CEO Bruno Strigini said: "Sickle-cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease.

"With this acquisition, Novartis is able to leverage its leadership in haematology research to advance development of a potential new treatment option for patients living with this debilitating condition."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"Novartis obtained the right to acquire Selexys and SelG1 in 2012."

SCD is a hereditary blood disorder characterised by sickle-shaped red blood cells and a lifelong disease with many forms that can range in clinical severity, from asymptomatic to life-threatening.

The major contributors for healthcare encounters in SCD are Vaso-occlusive crises or pain crises that occur episodically when these red blood cells block blood flow through blood vessels.

Selexys Pharmaceuticals president and CEO Dr Scott Rollins said: "Furthermore, the acquisition of Selexys by Novartis represents an important step in the continued development of SelG1, a novel, potential first-in-class therapy for patients with this underserved life-threatening disease."

Novartis obtained the right to acquire Selexys and SelG1 in 2012.

Image: Novartis headquarters in Basel. Photo: courtesy of –Andrew- from Flickr.